Identification of a conserved linear epitope at the N terminus of the rabies virus glycoprotein

References

1. Badrane H., Bahloul C., Perrin P., Tordo N. 2001; Evidence for two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J Virol 75:3268–3276 [CrossRef]
   [Google Scholar]
2. Cliquet F., Aubert M., Sagné L. 1998; Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. J Immunol Methods 212:79–87 [CrossRef]
   [Google Scholar]
3. Cliquet F., McElhinney L. M., Servat A., Boucher J. M., Lowings J. P., Goddard T., Mansfield K. L., Fooks A. R. 2004; Development of a qualitative indirect ELISA for the measurement of rabies virus-specific antibodies from vaccinated dogs and cats. J Virol Methods 117:1–8 [CrossRef]
   [Google Scholar]
4. Coulon P., Lafay F., Flamand A. 1993; Rabies virus antigenicity: an overview. Onderstepoort J Vet Res 60:271–275
   [Google Scholar]
5. Cox J. H., Dietzschold B., Schneider L. G. 1977; Rabies virus glycoprotein. II. Biological and serological characterization.. Infect Immun 16:754–759
   [Google Scholar]
6. Dietzschold B., Wiktor T. J., Macfarlan R., Varrichio A. 1982; Antigenic structure of rabies virus glycoprotein: ordering and immunological characterization of the large CNBr cleavage fragments. J Virol 44:595–602
   [Google Scholar]
7. Dietzschold B., Wunner W. H., Wiktor T. J., Lopes A. D., Lafon M., Smith C. L., Koprowski H. 1983; Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc Natl Acad Sci U S A 80:70–74 [CrossRef]
   [Google Scholar]
8. Dietzschold B., Gore M., Marchadier D. 7 other authors 1990; Structural and immunological characterization of a linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J Virol 64:3804–3809
   [Google Scholar]
9. Fooks A. R., McElhinney L. M., Brookes S. M., Johnson N., Keene V., Parsons G., Soldan A. 2002; Rabies antibody testing and the UK Pet Travel Scheme. Vet Rec 150:428–430
   [Google Scholar]
10. Gaudin Y., Ruigrok R. W. H., Tuffereau C., Knossow M., Flamand A. 1992; Rabies virus glycoprotein is a trimer. Virology 187:627–632 [CrossRef]
    [Google Scholar]
11. Gaudin Y., Raux H., Flamand A., Ruigrok R. W. H. 1996; Identification of amino acids controlling the low-pH-induced conformational change of rabies virus glycoprotein. J Virol 70:7371–7378
    [Google Scholar]
12. Grabowska A., Jameson C., Laing P., Jeansson S., Sjögren-Jansson E., Taylor J., Cunningham A., Irving W. L. 1999; Identification of type-specific domains within glycoprotein G of herpes simplex virus type 2 (HSV-2) recognized by the majority of patients infected with HSV-2, but not by those infected with HSV-1. J Gen Virol 80:1789–1798
    [Google Scholar]
13. Hooper D. C., Morimoto K., Bette M., Weihe E., Koprowski H., Dietzschold B. 1998; Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J Virol 72:3711–3719
    [Google Scholar]
14. Inoue S., Motoi Y., Kashimura T., Ono K., Yamada A. 2003; Safe and easy monitoring of anti-rabies antibody in dogs using His-tagged recombinant N-protein. Jpn J Infect Dis 56:158–160
    [Google Scholar]
15. Johnson N., Mansfield K. L., Fooks A. R. 2002a; Canine vaccine recipients recognize an immunodominant region of the rabies virus glycoprotein. J Gen Virol 83:2663–2669
    [Google Scholar]
16. Johnson N., McElhinney L. M., Smith J., Lowings P., Fooks A. R. 2002b; Phylogenetic comparison of the genus Lyssavirus using distal coding sequences of the glycoprotein and nucleoprotein genes. Arch Virol 147:2111–2123 [CrossRef]
    [Google Scholar]
17. Luo T. R., Minamoto N., Ito H., Goto H., Hiraga S., Ito N., Sugiyama M., Kinjo T. 1997; A virus-neutralizing epitope on the glycoprotein of rabies virus that contains Trp251 is a linear epitope. Virus Res 51:35–41 [CrossRef]
    [Google Scholar]
18. Ma B., Elkayam T., Wolfson H., Nussinov R. 2003; Protein–protein interactions: structurally conserved residues distinguish between binding sites and exposed protein surfaces. Proc Natl Acad Sci U S A 100:5772–5777 [CrossRef]
    [Google Scholar]
19. Ni Y., Tominaga Y., Honda Y., Morimoto K., Sakamoto S., Kawai A. 1995; Mapping and characterization of a sequential epitope on the rabies virus glycoprotein which is recognized by a neutralizing monoclonal antibody, RG719. Microbiol Immunol 39:693–702 [CrossRef]
    [Google Scholar]
20. Prehaud C., Coulon P., Lafay F., Thiers C., Flamand A. 1988; Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence. J Virol 62:1–7
    [Google Scholar]
21. Raux H., Coulon P., Lafay F., Flamand A. 1995; Monoclonal antibodies which recognize the acidic configuration of the rabies glycoprotein at the surface of the virion can be neutralizing. Virology 210:400–408 [CrossRef]
    [Google Scholar]
22. Roche S., Gaudin Y. 2002; Characterization of the equilibrium between the native and fusion-inactive conformation of rabies virus glycoprotein indicates that the fusion complex is made of several trimers. Virology 297:128–135 [CrossRef]
    [Google Scholar]
23. Seif I., Coulon P., Rollin P. E., Flamand A. 1985; Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein. J Virol 53:926–934
    [Google Scholar]
24. Smith G. P., Scott J. K. 1993; Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol 217:228–257
    [Google Scholar]
25. Smith R. A., Myers N. B., Robinson M., Hansen T. H., Lee D. R. 2002; Polymorphism at position 97 in MHC class I molecules affects peptide specificity, cell surface stability, and affinity for β ₂-microglobulin. J Immunol 169:3105–3111 [CrossRef]
    [Google Scholar]